| Title |
Author |
Type |
Date |
Words |
| The Cure Panel Talk Show Featuring Physicians in Conversation with Patients About New Treatments Creates National Interest. |
|
|
Dec 16, 2012 |
790 |
| Ligand Initiates Pivotal Trial of Captisol-Enabled[R], Propylene Glycol-Free Melphalan in Patients with Multiple Myeloma. |
|
|
Dec 10, 2012 |
1058 |
| Canada : Onyx Pharmaceuticals Completes Enrollment in FOCUS Phase 3 Carfilzomib Trial in Patients with Relapsed and Refractory Multiple Myeloma. |
|
|
Oct 16, 2012 |
229 |
| NextBio Teams With Emory University for Cancer Biomarker Discovery. |
|
|
Sep 24, 2012 |
649 |
| First-Line Multiple Myeloma Patient Share in Europe is Variable by Country and Dependent on Patient Eligibility for Stem-Cell Transplantation; Overall, Janssen's Velcade Dominates. |
|
|
Aug 28, 2012 |
686 |
| Senesco Announces that SNS01-T Showed Good Tolerability and Stable Disease in Newly Completed First Cohort of Phase 1b/2a Multiple Myeloma Trial. |
|
|
Aug 15, 2012 |
1094 |
| Onyx Pharmaceuticals Announces Kyprolis(TM) Study Published in the Medical Journal Blood. |
|
|
Jul 25, 2012 |
1487 |
| Canada : Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis (carfilzomib) for Injection. |
|
|
Jul 21, 2012 |
406 |
| Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM) (carfilzomib) for Injection. |
|
|
Jul 20, 2012 |
1786 |
| Kyprolis[TM] (carfilzomib) for Injection Receives Accelerated Approval from FDA for Advanced Multiple Myeloma. |
|
|
Jul 20, 2012 |
986 |
| Ligand Licensee Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis[TM] (carfilzomib) for Injection. |
|
|
Jul 20, 2012 |
1406 |
| Onyx Pharmaceuticals Initiates Phase 3 Kyprolis(TM) Head-to-Head Comparison Trial vs. Velcade in Patients with Relapsed Multiple Myeloma. |
|
|
Jul 2, 2012 |
1099 |
| Primary solitary extramedullary plasmacytoma of the tongue. |
Onal, Cem; Oymak, Ezgi; Uguz, Aysun; Ergin, Melek |
Case study |
Jul 1, 2012 |
2295 |
| Millennium Initiates TOURMALINE-MM1 Pivotal Phase 3 Trial of MLN9708 in Patients With Relapsed and/or Refractory Multiple Myeloma. |
|
|
Jun 28, 2012 |
468 |
| Onyx Pharmaceuticals and the University of Texas MD Anderson Cancer Center Announce Strategic Alliance in Multiple Myeloma and Lymphoma. |
|
|
Jun 4, 2012 |
949 |
| Drug combination highly effective for newly diagnosed myeloma patients. |
|
|
Jun 4, 2012 |
574 |
| Pre-Clinical Data Demonstrates Promising Potential of MannKind's IRE1 Inhibitor to Treat Multiple Myeloma. |
|
|
May 31, 2012 |
720 |
| Over 90 Percent of Surveyed Hematologist-Oncologists in the U.S. are Aware that Takeda/Millennium's Subcutaneous Velcade is Approved for the Treatment of Myeloma. |
|
|
May 22, 2012 |
750 |
| Distended epidural varix. |
Schettino, Chris; Horner, Neil; Knightly, Jack |
Case study |
Jan 1, 2012 |
1122 |
| Southampton Varsity research reveals new ways to treat blood cancers. |
|
|
Dec 22, 2011 |
456 |
| Mayo Clinic Study May Help Physicians Determine How Patients Will Respond to Multiple Myeloma Therapy. |
|
|
Dec 20, 2011 |
477 |
| The Multiple Myeloma Research Foundation (MMRF) Announces Four Leading Academic Cancer Centers as Clinical Sites for Landmark Study. |
|
|
Dec 19, 2011 |
1010 |
| Mayo Clinic Study May Help Physicians Determine How Patients Will Respond to Multiple Myeloma Therapy. |
|
|
Dec 15, 2011 |
468 |
| Landmark VISTA Trial Shows Significant Long-Term Overall Survival Benefit of VELCADE (Bortezomib) in Patients With Previously Untreated Multiple Myeloma. |
|
|
Dec 12, 2011 |
1620 |
| Multiple Myeloma Research Consortium (MMRC) Welcomes the Barbara Ann Karmanos Cancer Institute as Member Institution. |
|
|
Dec 2, 2011 |
769 |
| AB Science Announces Recruitment of First Patient in Phase 3 Study of Masitinib in Multiple Myeloma. |
|
Clinical report |
Oct 17, 2011 |
1016 |
| Multiple myeloma presenting as acute renal failure. |
Kuo, Vincent C.; Fenves, Andrew Z.; Mehta, Ankit N. |
Clinical report |
Oct 1, 2011 |
3323 |
| Multiple Myeloma Research Foundation (MMRF) Announces First Patient Enrolled in Landmark 1000-Patient Study, with Four World-Class Cancer Centers as First Clinical Sites. |
|
|
Sep 20, 2011 |
1178 |
| Researchers Find RapidArc Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers. |
|
|
Aug 8, 2011 |
1210 |
| KP govt to provide free treatment for blood cancer patients. |
|
|
Aug 8, 2011 |
110 |
| Millennium Submits Supplemental New Drug Application with FDA for Long-Term Overall Survival Results of VELCADE in Previously Untreated Multiple Myeloma. |
|
|
Jul 19, 2011 |
1637 |
| Eighth Annual Multiple Myeloma Research Foundation (MMRF) Race for Research: Tri-State 5K Walk/Run Raises Over $335,000 for Cancer Research. |
|
|
Jun 14, 2011 |
905 |
| Ninth Annual Multiple Myeloma Research Foundation (MMRF) Laugh for Life: New York Raises Over $620,000 for Blood Cancer Research. |
|
|
May 17, 2011 |
1026 |
| The International Myeloma Foundation Says Major Medical Meeting in Paris Will Support New Treatment Options for Patients. |
|
|
May 3, 2011 |
784 |
| The Journal of Clinical Oncology Publishes Phase 3 XGEVA(TM) (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma. |
|
Clinical report |
Feb 22, 2011 |
2449 |
| The Highest Proportion of Surveyed Oncologists and MCOs Indicate That Bortezomib/Lenalidomide/Dexamethasone is the Most Efficacious Treatment for Relapsed/Refractory Multiple Myeloma, When Compared to Other Currently Available Therapies. |
|
|
Jan 31, 2011 |
694 |
| Multiple Myeloma Research Foundation (MMRF) Invests $3 Million in Development of Next-Generation Treatments. |
|
|
Jan 6, 2011 |
1026 |
| Secondary cancers cloud myeloma drug. |
|
|
Dec 14, 2010 |
746 |
| VELCADE Induction Followed by VELCADE Maintenance Improves Clinical Outcomes in Previously Untreated Multiple Myeloma Patients. |
|
Clinical report |
Dec 9, 2010 |
2446 |
| REVLIMID[R] Data in Patients with Multiple Myeloma Evaluating Surival Rates with Low- and High-Dose Dexamethasone with Respect to Age. |
|
Clinical report |
Dec 6, 2010 |
2461 |
| Webcast Alert: Continuous Therapy in Multiple Myeloma - Science Media Workshop. |
|
|
Dec 6, 2010 |
501 |
| Updated Clinical Results from REVLIMID[R] Continuous Treatment Phase III Study Show Statistically Significant Improvement in Progression-Free Survival in Patients Newly Diagnosed with Multiple Myeloma. |
|
Clinical report |
Dec 6, 2010 |
2748 |
| Array BioPharma's Arry-520 Demonstrates Single Agent Activity in Advanced Multiple Myeloma Patients. |
|
|
Dec 4, 2010 |
1274 |
| Phase III Study Evaluating REVLIMID[R] in Patients with High-Risk Smoldering Multiple Myeloma Reported Statistically Significant Reduction in Risk of Disease Progression. |
|
|
Dec 4, 2010 |
2617 |
| Webcast Alert: Continuous Therapy in Multiple Myeloma - Science Media Workshop. |
|
|
Dec 1, 2010 |
469 |
| Bisphosphonate-associated osteonecrosis of the jaw. |
Ferrara, Mark G. |
Case study |
Dec 1, 2010 |
2078 |
| Webcast Alert: Continuous Therapy in Multiple Myeloma - Science Media Workshop. |
|
|
Nov 30, 2010 |
501 |
| Improving multiple myeloma diagnosis. |
|
Brief article |
Nov 1, 2010 |
188 |
| Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma. |
|
Clinical report |
Aug 12, 2010 |
1239 |
| EMEA Approves Update to Velcade(R) (bortezomib) Label to Include Survival Benefit in Previously Untreated Patients with Multiple Myeloma. |
|
|
Jun 15, 2010 |
964 |
| EMA Approves Update to Velcade(R) (bortezomib) Label to Include Long Term (3 Year Follow up) Overall Survival Benefit in Previously Untreated Patients with Multiple Myeloma. |
|
|
Jun 15, 2010 |
1140 |
| Takeda to Co-Promote VELCADE[R] (bortezomib) for Injection in Japan. |
|
|
May 10, 2010 |
1436 |
| Journal of Clinical Oncology Publishes Data on Overall Survival Benefit of VELCADE[R] (Bortezomib) for Injection in Patients with Previously Untreated Multiple Myeloma. |
|
|
Apr 29, 2010 |
1560 |
| CombinatoRx Discovers Novel Multi-Target Mechanism for the Treatment of Hematologic Malignancies. |
|
|
Apr 14, 2010 |
645 |
| Multiple Myeloma Research Foundation (MMRF) Grants $1.0 Million Each to Intellikine, Inc. and Tragara Pharmaceuticals, Inc. to Advance Next-Generation Therapies for Multiple Myeloma. |
|
|
Mar 29, 2010 |
843 |
| Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers. |
|
|
Mar 19, 2010 |
537 |
| Disseminated plasmacytoma of the thyroid. |
Park, Brian J.; Kalish, Randy J.; Vercillo, Arthur P. |
Clinical report |
Mar 1, 2010 |
1318 |
| Takeda revises Velcade starting dose for patients with hepatic impairment. |
|
Brief article |
Feb 9, 2010 |
153 |
| More Good News for Myeloma Patients Could Change Patterns of Treatment. |
|
|
Dec 18, 2009 |
548 |
| VELCADE[R] (Bortezomib) for Injection Based Therapy Delivers Sustained Overall Survival Advantage in Patients with Previously Untreated Multiple Myeloma. |
|
Clinical report |
Dec 8, 2009 |
1826 |
| VELCADE[R] (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma. |
|
Clinical report |
Dec 7, 2009 |
1842 |
| Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multiple Myeloma. |
|
|
Dec 7, 2009 |
1329 |
| New 3-drug combo may effectively treat multiple myeloma. |
|
|
Dec 6, 2009 |
421 |
| Multiple Myeloma Research Foundation's (MMRF) Fall Gala Raises More Than $1.8 Million to Advance Cancer Research. |
|
|
Oct 27, 2009 |
696 |
| Cancer patients given a boost; A new treatment could give patients in the North East with certain types of cancer a greater chance of survival. Health Reporter HELEN RAE explains. |
|
|
Oct 26, 2009 |
607 |
| New Way of Therapy for Multiple Myeloma Offered. |
|
Clinical report |
Oct 25, 2009 |
465 |
| New treatment for North's blood cancer victims. |
|
|
Oct 17, 2009 |
213 |
| Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases. |
|
|
Sep 21, 2009 |
2604 |
| Genzyme's Mozobil approved by EU for treating certain cancer patients requiring a stem cell transplant. |
|
|
Aug 1, 2009 |
241 |
| The International Myeloma Foundation Says Medicare Decision to Cover PET Scans Can Improve Disease Staging and Treatment Planning. |
|
|
Apr 6, 2009 |
607 |
| Multiple Myeloma Research Foundation (MMRF) Grants $1.0 Million to Aileron Therapeutics and Astex Therapeutics to Advance New Therapies for Multiple Myeloma. |
|
|
Mar 2, 2009 |
805 |
| VELCADE(R) (bortezomib) Findings Reinforce Efficacy and Survival Across Multiple Patient Populations. |
|
|
Dec 9, 2008 |
796 |
| ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings Reported at ASH Annual Meeting. |
|
Clinical report |
Dec 9, 2008 |
771 |
| Gene variants can predict mortality in multiple myeloma. |
Sullivan, Michele G. |
Disease/Disorder overview |
Dec 1, 2008 |
848 |
| Scleredema-associated IgA myeloma with myelofibrosis in a young adult: a case report/Genc bir yetiskinde miyelofibroz ile sklerema iliskili IgA miyelom: bir vaka raporu. |
Rao, Seema; Kar, Rakhee; Pati, Hara Prasad; Saxena, Renu |
Case study |
Dec 1, 2008 |
1237 |
| A rare presentation of multiple myeloma: Tc-99m MIBI SPECT imaging of orbital involvement/Multiple myeloma'nin nadir bir gorunumu: Orbital tutulumun Tc-99m MIBI SPECT goruntulemesi. |
Sivrikoz, Ilknur Ak; Gulbas, Zafer |
Report |
Dec 1, 2008 |
555 |
| 'I've enough on my plate with fighting cancer, now I have to fight the NHS' Peter's appeal for treatment rejected by NHS Trust. |
|
|
Nov 22, 2008 |
572 |
| Multiple Myeloma Research Foundation's (MMRF) Annual Gala Raises More Than $1.5 Million to Advance Cancer Research. |
|
|
Nov 4, 2008 |
502 |
| As a treatment for multiple myeloma, autologous stem cell transplantation can be performed on an outpatient basis, resulting in shorter hospital stays and low treatment-related mortality, according to a report in the Mayo Clinic Proceedings for October. |
|
Brief article |
Oct 20, 2008 |
240 |
| Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011 in Patients with Multiple Myeloma. |
|
|
Oct 16, 2008 |
931 |
| The Multiple Myeloma Research Consortium (MMRC) Announces Initiation of Phase 1B Study of Elotuzumab (HuLuc63) Monoclonal Antibody in Combination with REVLIMID and dexamethasone. |
|
|
Oct 13, 2008 |
665 |
| The International Myeloma Foundation Applauds Expansion of VELCADE(R) for Previously Untreated Patients in Europe and Canada. |
|
|
Sep 29, 2008 |
486 |
| A case of multiple myeloma with double malarial infection/Cifte malarya enfeksiyonlu multipl miyelom olgusu. |
Chandra, Harish; Chandra, Smita |
Case study |
Sep 1, 2008 |
363 |
| Patients kept in dark over new drugs; The World Today. |
|
|
Aug 26, 2008 |
171 |
| Cancer 'patients kept in the dark' Specialists not telling of new treatments. |
|
|
Aug 26, 2008 |
624 |
| WALES: 'Cancer patients kept in the dark'. |
|
|
Aug 26, 2008 |
234 |
| WORLD TODAY: Patients kept in the dark. |
|
|
Aug 26, 2008 |
96 |
| Cancer patients 'kept in the dark'. |
|
|
Aug 26, 2008 |
102 |
| Treatment woes. |
|
|
Aug 26, 2008 |
133 |
| The Multiple Myeloma Research Consortium (MMRC) Announces Initiation of First Four-Drug Combination Study to Treat Newly Diagnosed Multiple Myeloma Patients. |
|
|
Aug 13, 2008 |
722 |
| The Multiple Myeloma Research Consortium (MMRC) Announces the Initiation of Phase I/II Study of Elotuzumab (Huluc63) Monoclonal Antibody in Combination with Velcade. |
|
Report |
Jul 18, 2008 |
677 |
| REVLIMID(R) Data for Newly Diagnosed Multiple Myeloma Reported at a Satellite Symposium During the 13th European Hematology Association Congress. |
|
|
Jun 16, 2008 |
1026 |
| New Analysis of Phase III Studies Shows That REVLIMID(R) Plus Dexamethasone Yielded an Estimated Mean Survival of 5.6 Life Years for Patients with Multiple Myeloma. |
|
|
Jun 14, 2008 |
899 |
| The International Myeloma Foundation Says Thalidomide Approval in Europe Could Provide Survival Benefits to Newly Diagnosed Myeloma Patients. |
|
|
Apr 21, 2008 |
607 |
| Myeloma patients flock to Little Rock. |
Hengel, Mark |
|
Mar 24, 2008 |
1912 |
| The International Myeloma Foundation Says Study Shows 90% Overall Response for Patients with New REVLIMID(R) Combination. |
|
|
Jan 4, 2008 |
586 |
| Gloucester Pharmaceuticals Announces Positive Interim Results of Phase I/II Study in Patients with Multiple Myeloma at the 2007 American Society of Hematology (ASH) Annual Meeting. |
|
|
Dec 10, 2007 |
793 |
| Extramedullary plasmacytoma of the larynx: A case report from Japan. |
Kusunoki, Takeshi; Ikeda, Katsuhisa; Murata, Kiyotaka; Nishida, Shozo; Tsubaki, Masanobu |
|
Dec 1, 2007 |
1270 |
| Updated REVLIMID(R) (Lenalidomide) Plus Dexamethasone Data in Previously Treated Multiple Myeloma Reported in The New England Journal of Medicine. |
|
Clinical report |
Nov 21, 2007 |
1782 |
| Moffitt Cancer Center Takes Part in Newly Published Study in This Week's New England Journal of Medicine. |
|
Report |
Nov 21, 2007 |
824 |
| Thalidomide hope in cancer battle. |
|
|
Oct 5, 2007 |
305 |
| Recurrence of isolated multiple myeloma in the skull base: a case report and review of the literature. |
Husein, Omar F.; Jacob, Abraham; Massick, Douglas D.; Welling, D. Bradley |
Clinical report |
Sep 1, 2007 |
2537 |
| The diagnostic footprints--a case study. |
Hoy, Barbara A. |
Case study |
Aug 1, 2007 |
1260 |
| Genzyme says phase 3 Mozobil trials meet primary endpoints for treating non-Hodgkin's lymphoma, multiple myeloma. |
|
|
Aug 1, 2007 |
474 |
| The European Myeloma Platform Applauds the EMEA Approval of REVLIMID and Supports Efforts to Quickly Bring the Oral Therapy to Patients Across Europe. |
|
|
Jun 20, 2007 |
385 |
| Revlimid(R) Clinical Study Reports Survival Advantage for Patients Newly Diagnosed With Multiple Myeloma at European Hematology Meeting. |
|
Clinical report |
Jun 11, 2007 |
1104 |
| The approach to the management of multiple myeloma has changed over the past decade. |
Thomson, Jackie |
Clinical report |
Jun 1, 2007 |
1819 |
| ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma. |
|
|
Apr 4, 2007 |
707 |
| Millennium discovers biomarkers potentially predictive of response to VELCADE. |
|
|
Apr 1, 2007 |
717 |
| Multiple myeloma responds to new regimens. |
Wilson, Bruce |
|
Mar 15, 2007 |
692 |
| NCCN Updates Multiple Myeloma Guidelines. |
|
|
Jan 8, 2007 |
627 |
| Giant cell arteritis mimicking multiple myeloma; diagnosed by PET scan. |
Patil, Soma S. |
|
Nov 1, 2006 |
1094 |
| Lenalidomide is effective in relapsed multiple myeloma. |
Worcester, Sharon |
|
Feb 1, 2006 |
213 |
| Pharmion Provides EU Registration Strategy Update for Thalidomide. |
|
|
Jan 10, 2006 |
1035 |
| Diagnostic accuracy of Cystatin C as a marker of kidney disease in patients with multiple myeloma: calculated glomerular filtration rate formulas are equally useful. |
Lamb, Edmund J.; Stowe, Helen J.; Simpson, David E.; Coakley, Anthony J.; Newman, David J.; Leahy, M |
|
Oct 1, 2004 |
3421 |
| Double stem cell transplant after HDC improves survival in multiple myeloma patients. |
|
|
Feb 16, 2004 |
382 |
| Tandem transplant: 60% remission in Myeloma. (Reduced Relapse and Mortality). |
DeMott, Kathryn |
|
Mar 1, 2002 |
532 |
| Novel agent stabilizes, aids refractory Myeloma. (Clinical Trials Slated for PS-341). |
DeMott, Kathryn |
|
Mar 1, 2002 |
325 |
| CELLPRO BEGINS PHASE III TRIAL IN MULTIPLE MYELOMA; New Trial Designed to Demonstrate Tumor-Cell Depletion. |
|
|
Jan 16, 1995 |
784 |
